0001104659-22-093714.txt : 20220823 0001104659-22-093714.hdr.sgml : 20220823 20220823163057 ACCESSION NUMBER: 0001104659-22-093714 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220819 FILED AS OF DATE: 20220823 DATE AS OF CHANGE: 20220823 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cramer Pamela J. CENTRAL INDEX KEY: 0001873517 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 221187899 MAIL ADDRESS: STREET 1: C/O RHYTHM PHARMACEUTICALS STREET 2: 222 BERKELEY STREET, SUITE 1200 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm2224302-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-08-19 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001873517 Cramer Pamela J. 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 Chief Human Resources Officer Common Stock 2022-08-19 4 M 0 13493 19.02 A 15717 D Common Stock 2022-08-19 4 S 0 13493 24.83 D 2224 D Stock Option (Right to Buy) 19.02 2022-08-19 4 M 0 13493 0 D 2031-07-25 Common Stock 13493 61507 D The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $24.79 to $24.86. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The stock options were granted on July 26, 2021. 25% of the shares subject to the option vest and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. /s/ Hunter Smith, attorney-in-fact for Pamela J. Cramer 2022-08-23